Fast Identification of Pathogen in the Setting of Hospital-acquired Pneumonia Using Ion Mobility Spectrometry

Identification of Microbes Through Detection of Pathogen Specific Volatile Compound Patterns, Using Multi-capillary Column Coupled Ion Mobility Spectrometry (MCC-IMS) in the Setting of Hospital-acquired Pneumonia

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01624181

Enrollment

Registered

2012-06-20

Start date

2012-06-30

Completion date

2012-09-30

Last updated

2013-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Lower Respiratory Tract Infection, Pneumonia

Keywords

ion mobility spectrometry, hospital-acquired pneumonia, microbiological investigation, intensive care

Brief summary

With this study the investigators want to determine, if a fast identification of germs, causing hospital-acquired infections of the lower respiratory tract, is possible through the use of MCC-IMS technology - a method that allows on time detection and identification of very small amounts of substances in gas samples. Therefore aspiration samples from the respiratory tracts of ventilated patients, which are suspected to develop such an infection, will be collected, cultivated and analyzed by MCC-IMS. The investigators want to determine if MCC-IMS diagnostic could be a faster alternative to conventional microbiological methods. The results of the MCC-IMS analyses therefore will be compared with results of conventional microbiological methods.

Detailed description

In this clinical feasibility study it is to be investigated if MCC-IMS analyses over clinical samples from ventilated critically ill patients could be a fast and secure alternative to conventional microbiological diagnostic methods in the identification of human pathogenic microbes in the setting of hospital-acquired pneumonia. Therefore aspiration samples from intubated and ventilated critically ill patients, which are suspected to develop such an infection, will be collected and cultivated for a short period of time. The headspace over these cultures will be analyzed using MCC-IMS - a technology that allows on time detection and identification of very small amounts of substances in complex and humid gas samples. Conventional microbiological investigations, including MALDI-TOF, will be carried out parallel to the MCC-IMS analyses.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Inclusion criteria

* patient is at the hospital for more than 48 hours * patient is intubated and mechanically ventilated * clinical suspicion for an infection of the lower respiratory tract has been raised and decision for microbiological investigation of respiratory aspirate was made

Exclusion criteria

* patient is at the hospital for less than 48 hours * patient has been recruited for another clinical study * suspicion for an infection with a germ belonging to risk class 3 and 4 according to the german law (BioStoffV and TRBA, e.g. Mycobacterium tuberculosis)

Design outcomes

Primary

Measure	Time frame	Description
Time until pathogen identification through MCC-IMS	Up to 24 hours after sampling. Sampling (as an iclusion criterion) can be necessary anytime along the ICU stay of the patient (up to 12 months).	time from sampling until the availability of the results.
time until pathogen identification through conventional microbiological diagnostic methods	Up to 5 days after Sampling. Sampling (as an iclusion criterion) can be necessary anytime along the ICU stay of the patient (up to 12 months).	time from sampling until the availability of the results.

Secondary

Measure	Time frame	Description
length of ICU stay	time from ICU admission to ICU discharge of study patients (up to 12 months)	total LOS ICU
Type and dosage of administered antibiotic therapy	approximately 5 days. Starting with the day the samples are taken. Ending with the day on which the results microbiological test are made avaiable.	name and dosage of the antibiotic therapeutic agents used to threat the infection
morbidity	Starts for study patients with the ICU admission and ends two days after the start of the initial antibiotic therapy. (up to 12 Months)	morbidity of the critical ill patient at ICU admission, at the time of sampling and after two days of antibiotic therapy using the SAPS II scoring system.

Countries

Germany

Outcome results